EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving ...

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Management View Dave Rosa, President, CEO & Director, stated the company is projecting fiscal year 2026 sales to be "at least $10.5 million, ...

Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, earlier than previously guided. NeuroOne Medical is ...

CLEVELAND – Trigeminal neuralgia (TN) is a debilitating, chronic syndrome that causes sudden, severe, electric shock-like pain in the face. While TN isn’t life-threatening, it can severely alter ...

NeuroOne Medical Technologies Corporation announced that CEO Dave Rosa participated in an interview on Today’s Marketplace, discussing advancements in epilepsy treatment alongside Dr. Jessica Clark ...

The company is projecting fiscal 2026 revenues of "at least $10.5 million," which Rosa described as "a minimum 17% increase from fiscal year 2025." Rosa stated, "we expect to complete this limited ...

Trigeminal neuralgia (TN) is a debilitating, chronic syndrome that causes sudden, severe, electric shock-like pain in the face, according to a news release from University Hospitals. While TN isn’t ...

NeuroOne Medical Technologies Corporation NMTC recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain. The ...